BriefTea
Every story in sixty words
Get the free app no ads · no paywallExplained in plain English
Lp(a) is largely genetic, making lifestyle changes ineffective. Unlike other cholesterol, there's no widely available drug to lower it. This Novartis trial was a major hope for those with high Lp(a), who face increased heart disease risk, so its failure is a significant setback for future treatment options.
Stories that explain this
Novartis drug that cut cholesterol particle 78% failed to stop heart attacksRelated explainers
Can lowering cholesterol fail? What is a 'neutral' trial result? Why stop drug development now? Why is dementia so hard to treat? Why is AI hard to regulate? Why is AI regulation so hard? Why are asteroids hard to spot? Why are attacks hard to intercept?The full catalogue
Browse every card filed under L →We would like to count visits and see which links bring readers here. That means storing a random ID in your browser. No cookies, no ads, no profile. How it works.